N-(2-氨乙基)-4-溴苯磺酰胺 | 90002-56-5

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-氨乙基)-4-溴苯磺酰胺
• 英文名称: N-(2-aminoethyl)-4-bromobenzenesulfonamide
• 英文别名: N-<4-Brom-benzolsulfonyl>-aethylendiamin
• CAS: 90002-56-5
• 化学式: C₈H₁₁BrN₂O₂S
• 分子量: 279.158
• InChiKey: VSTXANIIZJECGG-UHFFFAOYSA-N

物化性质

• 熔点：
  112-114
• 沸点：
  394.9±52.0 °C(Predicted)
• 密度：
  1.582±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-(2-Aminoethyl) 4-bromobenzenesulfonamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-(2-Aminoethyl) 4-bromobenzenesulfonamide
CAS number: 90002-56-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H11BrN2O2S
Molecular weight: 279.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(2-氨乙基)-4-溴苯磺酰胺 、 虫草素 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 purine-6-(4-bromo-N-(2-ethylamine)benzenesulfonamide)-9-N-(3'-deoxy)ribofuranoside
  参考文献：
  名称：

  N-(2-乙基胺)苯磺酰胺基虫草素衍生物及其制备方法和应用

  摘要：

  本发明公开了一种N‑(2‑乙基胺)苯磺酰胺基虫草素衍生物及其制备方法和在抑制肿瘤细胞增殖方面的应用，通过对虫草素进行化学改性，制备出的N‑(2‑乙基胺)苯磺酰胺基虫草素衍生物。相对于虫草素，N‑(2‑乙基胺)苯磺酰胺基虫草素衍生物对MDA‑MB‑231、A549和HeLa细胞的增值抑制表现出更好活性。

  公开号：

  CN110669088B
• 作为产物：
  描述：

  4-溴苯磺酰氯 在 palladium on activated charcoal 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-(2-氨乙基)-4-溴苯磺酰胺
  参考文献：
  名称：

  新型 N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide) 衍生物的抗癌谱和抗炎作用

  摘要：

  在我们以往工作的基础上，设计合成了一系列新的 N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide)衍生物11a-o 。其抗癌和抗炎作用。最终目标化合物的抗癌谱是通过测试它们获得的，超过 60 种细胞系属于九种癌症。化合物11c显示出最高的抑制百分比，因此在最敏感的细胞系上测量其效力以确定其对每个细胞的 IC 50。此外，化合物11c在激酶组上进行了测试，以获得其生物靶标。化合物11c对 JNK1、JNK2、p38a 和 V600EBRAF 有很强的活性。所有最终目标化合物都针对四种激酶进行了测试，以建立结构活性关系。对化合物11c进行细胞周期分析以检查在哪个阶段受11c影响。除了测试它们对相同细胞的细胞毒性作用外，还通过测试它们对原始 264.7 巨噬细胞抑制一氧化氮释放和前列腺素 E2 产生的能力来筛选最终目标化合物的抗

  DOI：

  10.1016/j.bioorg.2021.105424

文献信息

• Design, synthesis,<i>in vitro</i>anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
  作者：Mohammed S. Abdel-Maksoud、Mohammed I. El-Gamal、Mahmoud M. Gamal El-Din、Chang Hyun Oh

  DOI：10.1080/14756366.2018.1530225

  日期：2019.1.1

  Abstract The present work describes the design and synthesis of a novel series of 1,3-diaryl-4-sulfonamidoarylpyrazole derivatives 1a–q and 2a–q and their in vitro biological activities. The target compounds were evaluated for antiproliferative activity against NCI-60 cell line panel. Compounds 1c, 1g, 1k–m, 1o, 2g, 2h, 2k–m, 2o, and 2q showed the highest mean inhibition percentages at 10 µM single-dose

  抽象的 目前的工作描述了一系列新型的1,3-二芳基-4-磺酰胺基芳基吡唑衍生物1a-q和2a-q的设计和合成及其体外生物学活性。评价目标化合物对NCI-60细胞系的抗增殖活性。化合物1c，1g，1k–m，1o，2g，2h，2k–m，2o和2q在10 µM单剂量试验中显示出最高的平均抑制百分比，并被选择以5剂量模式进行试验。在60个细胞系中确定了最有效的化合物的IC 50。化合物2l对具有IC 50的不同细胞系表现出最强的活性针对A498肾癌细胞系的0.33 µM。在一组20种激酶中测试了化合物21，以确定其分子靶标，并定义了其对最敏感激酶的IC 50值。还研究了化合物2l的体外稳定性和体内药代动力学特征。
• Synthesis of New Triarylpyrazole Derivatives Possessing Terminal Sulfonamide Moiety and Their Inhibitory Effects on PGE2 and Nitric Oxide Productions in Lipopolysaccharide-Induced RAW 264.7 Macrophages
  作者：Mohammed S. Abdel-Maksoud、Mohammed I. El-Gamal、Mahmoud M. Gamal El-Din、Yunji Choi、Jungseung Choi、Ji-Sun Shin、Shin-Young Kang、Kyung Ho Yoo、Kyung-Tae Lee、Daejin Baek、Chang-Hyun Oh

  DOI：10.3390/molecules23102556

  日期：——

  This article describes the design, synthesis, and in vitro anti-inflammatory screening of new triarylpyrazole derivatives. A total of 34 new compounds were synthesized containing a terminal arylsulfonamide moiety and a different linker between the sulfonamide and pyridine ring at position 4 of the pyrazole ring. All the target compounds were tested for both cytotoxicity and nitric oxide (NO) production

  本文介绍了新型三芳基吡唑衍生物的设计、合成和体外抗炎筛选。总共合成了 34 种新化合物，它们包含末端芳基磺酰胺部分和磺酰胺和吡唑环 4 位吡啶环之间的不同接头。测试了所有目标化合物在脂多糖 (LPS) 诱导的 RAW 264.7 巨噬细胞中的细胞毒性和一氧化氮 (NO) 产生抑制。化合物 1b、1d、1g、2a 和 2c 显示出最高的 NO 抑制百分比和最低的细胞毒性作用。测试了最有效的衍生物在 LPS 诱导的 RAW 264.7 巨噬细胞中抑制前列腺素 E2 (PGE2) 的能力。确定了对一氧化氮抑制、PGE2 抑制和细胞活力的 IC50。此外，1b、1d、1g、2a、
• Design, Synthesis and Anticancer Profile of New 4-(1H-benzo[d]imidazol-1-yl)pyrimidin-2-amine-Linked Sulfonamide Derivatives with V600EBRAF Inhibitory Effect
  作者：Mohammed S. Abdel-Maksoud、Ahmed A. B. Mohamed、Rasha M. Hassan、Mohamed A. Abdelgawad、Garri Chilingaryan、Samy Selim、Mohamed S. Abdel-Bakky、Mohammad M. Al-Sanea

  DOI：10.3390/ijms221910491

  日期：——

  A new series of 4-(1H-benzo[d]imidazol-1-yl)pyrimidin-2-amine linked sulfonamide derivatives 12a–n was designed and synthesized according to the structure of well-established V600EBRAF inhibitors. The terminal sulfonamide moiety was linked to the pyrimidine ring via either ethylamine or propylamine bridge. The designed series was tested at fixed concentration (1 µM) against V600EBRAF, finding that

  根据成熟的 V600EBRAF 抑制剂的结构，设计并合成了一系列新的 4-(1 H- benzo[ d ]imidazol-1-yl)pyrimidin-2-amine 连接的磺酰胺衍生物12a-n。末端磺酰胺部分通过乙胺或丙胺桥连接到嘧啶环。设计的系列在固定浓度 (1 µM) 下针对 V600EBRAF 进行测试，发现12e、12i和12l在所有目标化合物中表现出最强的抑制活性，12l的 IC 50最低，为 0.49 µM。他们在 NCI 60 癌细胞系上进一步筛选以揭示12e显示出对多种癌细胞系的最显着的生长抑制。因此，进行了12e 的细胞周期分析以研究对细胞周期进程的影响。最后，进行虚拟对接研究以深入了解 vemuRAfenib、12i、12e和12l的合理结合模式。
• Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF
  作者：Mohammed S. Abdel-Maksoud、Eslam M.H. Ali、Usama M. Ammar、Karim I. Mersal、Kyung Ho Yoo、Chang-Hyun Oh

  DOI：10.1016/j.bmc.2020.115493

  日期：2020.6

  Several pyrrolo[2,3-b]pyridine-based B-RAF inhibitors are well known and some of them are currently FDA approved as anticancer agents. Based on the structure of these FDA approved V600EB-RAF inhibitors, two series of pyrrolo[2,3-b]pyridine scaffold were designed and synthesized in attempt to develop new potent V600EB-RAF inhibitors. The 38 synthesized compounds were biologically evaluated for their

  几种基于吡咯并[2,3-b]吡啶的B-RAF抑制剂是众所周知的，其中一些目前已被FDA批准用作抗癌剂。根据这些FDA批准的V600EB-RAF抑制剂的结构，设计并合成了两个系列的吡咯并[2,3-b]吡啶骨架，以开发新的有效V600EB-RAF抑制剂。对38种合成化合物的单次剂量（10μM）的V600EB-RAF抑制作用进行了生物学评估。测试了具有高抑制百分数的化合物，以测定其相对于V600EB-RAF的IC50。化合物34e和35表现出最高的抑制作用，IC50值分别为0.085 µM和0.080 µM。为了进行过度的生物学评估，对合成的衍生物进行了六十种不同的人类癌细胞系测试。
• Aryne-Mediated [2,3]-Sigmatropic Rearrangement of Tertiary Allylic Amines
  作者：Juan Zhang、Zhi-Xiong Chen、Ting Du、Bing Li、Yonghong Gu、Shi-Kai Tian

  DOI：10.1021/acs.orglett.6b02344

  日期：2016.10.7

  3]-sigmatropic rearrangement of quaternary allylic ammonium ylides via in situ activation of tertiary allylic amines with arynes under mild conditions. Using 2-(trimethylsilyl)aryl triflates as aryne precursors, a range of tertiary allylic amines bearing electron-withdrawing groups underwent [2,3]-sigmatropic rearrangement to furnish structurally diverse homoallylic amines in moderate to good yields. The reaction

  已经建立了通过在温和条件下用芳烃原位活化叔烯丙基胺来[4,3]-σ重排季铵烯丙基铵的新策略。使用2-（三甲基甲硅烷基）芳基三氟甲磺酸酯作为芳烃前体，对一系列带有吸电子基团的叔烯丙基胺进行[2,3]-σ重排，以中等至良好的收率提供结构多样的均胺。该反应能够构建具有出色对映体纯度的四级立体中心和具有极高非对映选择性的官能化环丙烷。